Abstract GLUT4, the main insulin-responsive glucose transporter, plays a critical role in maintaining systemic glucose homeostasis and is subject to complicated metabolic regulation. GLUT4 expression disorder might cause insulin resistance, and over-expression of GLUT4 has been confirmed to ameliorate diabetes. Here, we reported that farnesoid X receptor (FXR) and its agonist chenodeoxycholic acid (CDCA) could induce GLUT4 transcription in 3T3-L1 and HepG2 cells. Furthermore, CDCA could increase the GLUT4 protein amount in C57BL/6J mice sex-dependently. The following progressive 5'-deletion analysis and site-mutation investigation further suggested that FXR could induce GLUT4 expression through FXR response element (FXRE) in the GLUT4 promoter. EMSA and knock-down of retinoid X receptor (RXR) indicated that FXR binds to the GLUT4-FXRE as a monomer and RXR does not participate in the FXR stimulation of GLUT4 expression. In addition, we demonstrated that FXR does not interfere with insulininduced GLUT4 translocation to plasma membrane. All these data thereby implied that FXR is a new transcription factor of GLUT4, further elucidating the potential role for FXR in glucose metabolism.
Introduction
Nowadays the incidences of diabetes mellitus have increased seriously and affected a growing number of people. Type 2 diabetes, caused by pancreatic beta-cells' failing to compensate fully for the insulin resistance, makes up about 90% of all cases and will result in various abnormalities if untreated [1] . The main insulin-responsive facilitative glucose transporter, GLUT4, locates exclusively in insulin target tissues (i.e. brown and white fat, skeletal and cardiac muscle) and plays a critical role in maintaining systemic glucose homeostasis [2, 3] . Glucose transport is an essential step in insulin action and 2 many studies have demonstrated the association between GLUT4 expression and diabetes. For example, GLUT4 expression was found to decrease both in type 1 and 2 diabetic subjects [4] [5] [6] . In rodent model, adipose-selective ablation of GLUT4 impairs insulin action in adipose, muscle and liver, leading to glucose intolerance and hyperinsulinaemia [7] , while over-expressing GLUT4 selectively in adipose tissue can enhance whole body glucose disposal and tolerance [8] . Similar results have also been obtained using muscle tissue [9, 10] . To date, a number of transcription factors and stimulus correlated with diabetes and metabolism, such as liver X receptor (LXR) [11] , Nuclear Factor I [12] , Olf-1/Early B cell factor [13] , insulin and glucose [14] , have been investigated in the exploration of their influences on GLUT4 expression.
The farnesoid X receptor (FXR, also named RIP14 and HRP1) is a nuclear receptor highly expressed in the liver, intestine, adrenal, kidney [15] and can also be detected in differentiating adipocytes [16] . FXR binds to various FXR response elements (FXREs) in different manners [17, 18] . Upon activation by bile acids (BA), its endogenous ligands [19] , FXR down-regulates BA synthesis via suppressing the rate-limiting enzyme cholesterol 7a hydroxylase (Cyp7a1) in order to prevent BA overload and toxicity [20] . Previous data have also confirmed the essential roles of BA and FXR in lipid metabolism [21] [22] [23] .
Recently, accumulating evidences have established the links between FXR and glucose metabolism. The first suggestion came from the epidemiological studies, in which patients with type 2 diabetes are subjected to higher risk for gallbladder disease [24] . This hypothesis was further confirmed by the observation that hepatic FXR mRNA decreased in diabetic rodent models and administration of insulin to STZ rats compromised this effect [25] . Later, FXR was indicated to regulate adipose cell function, peripheral insulin sensitivity and systemic glucose homeostasis by modulating several important genes involved in the insulin signaling pathways [16, 26, 27] . Nevertheless, the knowledge of the exact molecular mechanisms regarding FXR and GLUT4 is still unclear.
Taken together, the data above have provided compelling evidence to the potential association between FXR and GLUT4 expression. Here, our results showed that FXR was able to up-regulate GLUT4 expression as a transcription factor and an FXR response element was located in the GLUT4 gene promoter. Additionally, we demonstrated that FXR could not interfere with GLUT4 translocation to plasma membrane induced by insulin.
Materials and Methods

Materials
The restriction enzymes were purchased from New England Biolabs. Cell culture plastic ware was obtained from Corning Inc. DMEM, αMEM, F-12 culture medium and fetal bovine serum were from Invitrogen. Luciferase activities were assessed by using Dual Luciferase Assay System from Promega. Rosiglitazone was obtained from Caymen Chem. Co. GW9662 and guggulsterone were from Merck. LY249002, CDCA, biotin and Ca-panthothenate were from Sigma. The pCMX-hFXR plasmid was kindly provided by Stefan K. Westin (the Department of Biology, X-Ceptor Therapeutics Inc., San Diego, California). The pCMX-RXRα and pGL3-human GLUT4 promoter plasmids were kindly provided by Dr. Hilde I. Nebb (University of Oslo, N-0316 Oslo, Norway).
Cell culture 3T3-L1 cells were cultured in DMEM supplemented with 10% fetal bovine serum, 8mg/L biotin and 4mg/L Capantothenate (10%DMEM/FBS). Differentiation of 3T3-L1 cells was performed following the procedure of Frost and Lane [28] with some modifications. Preadipocytes were seeded, grown for 2 days post-confluence and incubated in medium containing 115μg/ml isobutylmethylxanthine, 0.39μg/ml dexamethasone and 1μg/ml insulin. After 3 days, medium was replaced with 10%DMEM/FBS containing 1μg/ml insulin. After 2 days, cells were cultured in 10%DMEM/FBS and refreshed every 2 days. HepG2 and HEK293 cells were respectively cultured in αMEM and DMEM supplemented with 10% fetal bovine serum.
Plasmid constructs
The mouse GLUT4 promoter (-3225bp ~ +181bp) was amplified by KOD polymerase (Toyobo) from mouse genome and ligated into NheI-and-XhoI-digested pGL3-Basic vector. With the plasmid (pGL3-mGLUT4 promoter) as the template, a series of progressive 5'-deletion promoter fragments were generated by PCR and then inserted into NheI-and-XhoIdigested pGL3-Basic vector. The two primers, 5 '-CGC CGG  CTA GCG TTG TGA AGG GCG TGT CCT ATG GC -3' and 5'-CGC CGG CTA GCG TTG TGA AGG GCG TGT TTA ATG GC -3', were used as 5' primers to construct the plasmids pGL3-mGLUT4-WT and pGL3-mGLUT4-MUT. Similarly, the serial 5'-deletion fragments of the human GLUT4 promoter were prepared by PCR, taking the pGL3-hGLUT4 promoter plasmid as the template. 5'-CTC CTC GAG GGG TGC TGT GAA GGG CGT GG -3' and 5'-CTG CTC GAG GGG TGC TGT GAA GGG CGT GGT TAG CGG GG -3' were used as 5' primers to construct the plasmids pGL3-hGLUT4-WT and pGL3-hGLUT4-MUT. The pSuperbasic-FXR and pSuperbasic-RXRα were constructed by inserting the coding sequences of siRNA into the pSuperbasic with BglII-HindIII sites. The sequences were GGG GAT GAG CTG TGT GTT G (FXR) and GCA CTA TGG AGT GTA CAG C (RXRα) according to the published data [29, 30] .
Transient transfection and Luciferase assay
The transfection efficiency of 3T3-L1 preadipocytes and HepG2 cells were evaluated by transfecting pEGFP-N1. For transient transfection, cells (24-well plate) were transfected with 600ng Luciferase reporter plasmid together with 20ng pRL-SV40 each well and refreshed with normal medium 5 hours later. After transfection 3T3-L1 preadipocytes were cultured for 2 days and differentiated. Compounds treatment and Luciferase assay were performed on the 12 th day of differentiation. EMSA FXRΔ110 (amino acids 111-473) and full-length RXRα were expressed and purified according to the published method [17] . FXRΔ110 and RXRα were amplified by PCR using pCMXhFXR and pCMX-RXRα as templates respectively and subcloned into pET-28a. The pET-28a-FXRΔ110 and pET-28a-RXRα were transformed into Escherichia coli (BL21(DE3)pLysS (Novagen)). Cultures were grown till the OD600 reached 0.8 and then induced with 0.33mM IPTG for additional 3 hours at 26°C. The cells were harvested and suspended in Binding Buffer (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 1 mM PMSF). After sonication on ice, lysates were centrifuged at 21,000×g for 20 min and the supernatant was subsequently loaded onto a nickel affinity column (Novagen) pre-equilibrated with Binding Buffer. The column was washed with Washing Buffer (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 50 mM imidazole, 1 mM PMSF) for 10 column volumes and proteins were eluted with Elution Buffer (20 mM Tris-HCl, pH 7.9, 500 mM NaCl, 200 mM imidazole, 1 mM PMSF) for 5 column volumes. The soluble protein fractions were then pooled and dialyzed against 25 mM HEPES, pH 7.6, 2 mM MgCl2, 20% glycerol, 1 mM EDTA, 100 mM KCl, 1 mM DTT, 1mM PMSF. Single-stranded oligonucleotides were synthesized from Invitrogen Inc. After annealing, the doublestranded oligonucleotides were labeled with T4 polynucleotide kinase (Takara) and [γ-32P]ATP. The labeled oligonucleotides were purified by using SephadexTM G-25 (Amersham Pharmacia Biotech). For EMSA assay, FXR was incubated for 10 min at room temperature in a total volume of 10μl including 2μl of EMSA Binding Buffer (Beyotime). After the radiolabeled oligonucleotides were added, the binding reaction was maintained at room temperature for 20 min. The protein-DNA complexes were then resolved on a 4% nondenaturing polyacrylamide gel in 0.5×Tris-borate buffer at 120V for 90min at 4°C. After electrophoresis, gels were dried and subjected to autoradiography. For CDCA test, the binding system was supplemented with indicated amount of CDCA before adding radiolabeled probes. The synthesized oligonucleotides were as follows: mouseWT: 5'-GGT GTT GTG AAG GGC GTG TCC TAT GGC -3'; mouseMUT: 5'-GGT GTT GTG AAG GGC GTG TTT AAT GGC -3'; humanWT: 5'-GTG CTG TGA AGG GCG TGG CCC GCG G -3'; humanMUT: 5'-GTG CTG TGA AGG GCG TGG TAA GCG G -3'.
ChIP assay 3T3-L1 cells were transfected with pCMX-hFXR and incubated in differentiation medium. On the 12 th day of differentiation, 3T3-L1 adipose cells were treated with 100 µM CDCA for 24 hours. ChIP assays were then performed according to the protocol of a commercial kit (Upstate Biotechnology, Waltham, MA). The antibody FXR C-20 (SantaCruz, Heidelberg, Germany) was used in the immunoprecipitation. The GLUT4 promoter region containing the FXRE was amplified by using a primer set of 5'-CAG CCA GCA CTA GGG CTA GGG GTG G-3' and 5'-GTG AGA CCC GCT TGA GGG GGA AAG-3'.
Western Blot analysis 3T3-L1 cells were seeded and differentiated in 24-well plates. After treatment with CDCA, the cells were harvested and the protein extracts were subjected to Western Blot. For animal assay, tissue proteins were extracted in lysis buffer (Beyotime) from white adipose tissue [31] via homogenization on ice. For all the experiments, the amount of GLUT4 protein was investigated by using GLUT4 antibody (R&D system, USA) and the loading volumes were normalized by GADPH antibody (Kangchen).
GLUT4 membrane translocation assay
The construction of the stable CHO (GLUT4) cell line and the GLUT4 membrane translocation assay were performed as previously described [32] . The CHO (GLUT4) cells plated in a 96-well plate were incubated in F-12 culture medium. After the cell density reached 90% confluence, pCMX-hFXR and control vector were transiently transfected. After treatment of DNA containing medium for 5 hours, cells were cultured in 10% DMEM/FBS for additional 48 hours. The GLUT4 membrane translocation assay was performed and analyzed by using IN Cell Analyzer 1000 system (GE Healthcare).
2-Deoxyglucose Uptake in 3T3-L1 Adipocytes
3T3-L1 cells were fully differentiated and then seeded onto 24 wells plate. After incubation in serum-free medium supplemented with CDCA (50 µM) for 12 hours, the medium was changed to Krebs buffer containing 170nM insulin for more 30 minutes (the last 5 minutes with 2-[ 3 H]-deoxy-Dglucose). The glucose uptake was stopped by ice-cold PBS and cells were lysed by 100 µl of 0.1% Triton. Radioactivity was finally calculated by scintillation counter. Cytochalasin B was used to measure nonspecific uptake, and the value was subtracted from all the data. Radioactivities were normalized by total protein concentration using BCA kit.
Animals
All animal experiments were carried out in accordance with the Regulations of Experimental Animal Administration issued by the State Committee of Science and Technology of the People's Republic of China on November 14, 1988 . C57BL/ 6J mice, 8 weeks of age (male 22-25 g, female 18-21 g) were supplied by Shanghai Experimental Animal Center, Chinese Academy of Sciences. The mice were housed under standard conditions (strict 12-h light/dark cycle, 22°C, 60% in humidity) in plastic cages and provided with unlimited access to water and food.
Mice were treated with CDCA (20mg/kg, body weight/ day) or its vehicle (sterilized water containing 10% solubilizen Tween-80) through intraperitoneal injection. After 10 days, mice were sacrificed. WAT from each mouse was isolated and subjected to western blot analysis as described above.
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Real-time quantitative RT-PCR
3T3-L1 cells were seeded and differentiated in 10-cm plates. After treatment with CDCA, total RNA was extracted from mature 3T3-L1 adipose cells using Rnase-free equipment (Axygen, Union City, CA) and Trizol reagent (Bio. Basic Inc, Canada) [33] . RNA was then reverse-transcribed using AMV Reverse Transcriptase and Oligo-p [5] 18 Primer (Generay Biotech). Real-time PCR was performed using SYBR Premix Ex Taq (TaKaRa) on DNA Engine Opticon 
Results
CDCA can induce GLUT4 expression in 3T3-L1 cells
To investigate the influence of FXR on GLUT4 transcription, the fully differentiated 3T3-L1 cells were initially treated for 48 hours with the natural potent FXR agonist CDCA for primarily inducing FXR target genes according to the published approach [18] . During the assay, GLUT4 mRNA levels were measured by semiquantitative RT-PCR (Fig. 1A) . A significant increase in GLUT4 mRNA amount could be thus observed in CDCA-treated compared with DMSO-treated 3T3-L1 cells. The increase induced by CDCA treatment was then quantified by real-time RT-PCR (Fig. 1B) . Moreover, CDCA (50µM) could obviously enhance GLUT4 protein amount in the mature 3T3-L1 adipose cells (Fig. 2E ).
FXR and its agonist CDCA activates the GLUT4 promoter in 3T3-L1 and HepG2 cells, while PPARγ and PI3K are not involved in FXR's regulation of GLUT4 expression
To further determine FXR and CDCA's effects on the mouse/human GLUT4 promoter, we performed transient transfections using 3T3-L1 cells and HepG2 cells. We found that CDCA stimulation could result in an induction of the mouse/human GLUT4 promoter activity in mature 3T3-L1 adipose cells dose-dependently ( Fig. 2A) . TO901317, a synthetic LXR ligand proved to up-regulate GLUT4 transcription, was taken as the positive control. In HepG2 cells, we also found that either over-expression of FXR or CDCA treatment could enhance the mouse GLUT4 promoter activity, while guggulsterone antagonized CDCA induction in a dosedependent manner (Fig. 2B) . To examine whether FXR and CDCA could also exert the same induction on the human GLUT4 promoter, similar tests were conducted (Fig. 2C) . Furthermore, such induction was FXRdependent as investigated by the subsequent knockdown (Fig. 2D ) and western blot assays (Fig. 2E) . Moreover, we have also investigated the possible effects of PPARγ and PI3K on FXR's regulation of human GLUT4 expression. During the assay, after transient transfection with pGL3-hGLUT4 promoter and pCMX-hFXR, HepG2 cells were treated with GW9662, Rosiglitazone and LY294002 for 48 hours (Fig. 2F) .
Accordingly, all the above-mentioned results thus demonstrated that FXR and CDCA could activate the GLUT4 promoter activity in HepG2 and 3T3-L1 cells, while PPARγ or PI3K might not be involved in FXR's regulation of GLUT4 expression. FXR might directly bind to the GLUT4 promoter as a transcription factor.
FXR and CDCA induce GLUT4 expression through a region bearing one nuclear receptor half-site
Since the above results have suggested that FXR might not influence GLUT4 expression through PPARγ-and PI3K-related signaling pathways, we therefore hypothesized that FXR might directly affect GLUT4 expression by certain responsive cis-elements in the GLUT4 promoter. To validate this hypothesis, we performed the following investigations. First of all, we analyzed the mouse and human GLUT4 promoter sequences that span about 3000 bp up-and down-stream from the transcription start sites. However, no typical FXRE, an inverted repeat (IR) of the TGACCT hexanucleotide core motif with 1-base pair spacing, was identified. Therefore, in order to localize the region through which FXR mediates GLUT4 expression, we conducted a progressive 5'-deletion analysis of the mouse and human GLUT4 promoter, in which serial truncated constructs were transiently transfected into HepG2 cells and FXR's effects on the transcription activities from various lengths of the mouse and human GLUT4 promoters were detected (Figs. 3A and B) . The results clearly revealed that the region between -93bp and +181bp of the mouse GLUT4 promoter was sufficient to retain the effect elicited by FXR, while deletion of the region from -93bp to -46bp almost abolished the enhancement, demonstrating that this region might be essential for FXR to exert its influence on the mouse GLUT4 promoter. As for the human GLUT4 promoter, the progressive 5'-deletion result indicated that the region from -87bp to -46bp partially abrogated FXR's induction, indicating that this human GLUT4 promoter region might response to FXR. We also confirm our results using 3T3-L1 adipose cells (Fig. 3C) . In addition, the similarity of these two mapped human and mouse GLUT4 promoter regions from the alignment assay also suggested the possibility of FXR binding to these sites, where it could be found that these two regions exhibited highly identity and a nuclear receptor half-site (TGTCCT in the mouse GLUT4 promoter and TGGCCC in the human GLUT4 promoter) was discovered (Fig. 3D) .
In an attempt to further verify the hypothesis that FXR mediates GLUT4 expression through the nuclear receptor half-sites as identified in the above-mentioned 5'-deletion analysis, we introduced mutations into these sites. The pGL3-mGLUT4-WT and pGL3-mGLUT4-MUT were transfected into HepG2 cells together with FXR-over-expression or CDCA-treatment. As expected, mutations in the core motif almost fully abrogated the ability of FXR or CDCA to induce the mouse GLUT4 promoter activity (Figs. 3E and G) . Meanwhile mutation of the FXRE in the human GLUT4 promoter also eliminated the induction (Figs. 3F and H) . Therefore, the induction of FXR on the GLUT4 promoter is FXREdependent. We also confirm our results using 3T3-L1 adipose cells (Fig. 3I) .
EMSA based confirmation of FXR binding to the FXRE in the GLUT4 promoter
In order to inspect FXR binding to the above identified mouse and human FXREs in vitro, we performed the electrophoretic mobility shift assay. In this assay, a DNAprotein complex was observed in the presence of FXR protein and oligonucleotides containing the mouse-GLUT4-FXRE, thus implying the binding of FXR to the FXRE, and such binding is specific as investigated by the fact that this DNA-protein complex could be competed in a concentration-dependent manner by increasing amounts of the unlabelled wild type oligonucleotides, but not by the mutated ones (Fig. 4A) . Moreover, CDCA could obviously promote DNA-protein complex formation (Fig. 4C ). In addition, the EMSA results also validated the FXR binding to the oligonucleotides containing the human (Figs. 4B and D) . We also performed chromatin immunoprecipitation (ChIP) to investigate whether FXR binds to GLUT4-FXRE in contact cells. Mature 3T3-L1 adipose cells were treated with DMSO or CDCA (100 µM) for 24 hours and FXR was observed to bind to GLUT4-FXRE after CDCA-stimulation (Fig. 4E) .
FXR-induced GLUT4 expression does not require the participation of RXR
Since it has been known that FXR is able to heterodimerize with RXR in the regulation of its target genes, we carried out the following experiments to address whether RXR also participates in regulating GLUT4 as the heterodimeric partner of FXR. First, HepG2 cells were treated with 9-cis retinoic acid together with or without CDCA after transiently transfected with pGL3-m/h-GLUT4-WT. We found that 9-cis retinoic acid alone did not increase the GLUT4 promoter activity, meanwhile 9-cis retinoic acid could neither significantly antagonize nor further increase the induction of GLUT4 transcriptional activity by CDCA (Figs. 5A and B) . Next, we performed siRNA-mediated knock-down of RXR in HepG2 cells and the results demonstrated that silencing RXR did not interfere with the effect of CDCA on the GLUT4 promoter activity (Figs. 5D and E) . Moreover, the EMSA-based assay also showed that no obvious DNA-heterodimer complex was observed and RXR could neither significantly enhance nor dampen the binding of FXR to the oligonucleotides containing the mouse-or human-GLUT4-FXRE (Figs. 5F and G). In conclusion, activating or silencing RXR had no effect on FXR's modulation towards GLUT4 expression. In other word, FXR binds to the FXREs as a monomer without the participation of RXR.
GLUT4 expression is induced in vivo by CDCA in a sex-dependent manner
To confirm the above-mentioned FXR-related results in vivo, we performed animal experiments for inspecting the potential influence of CDCA on GLUT4 expression. During the assay, WAT from each vehicle or CDCA treated mouse was taken out, homogenized and subjected to western blot. In male mice, GLUT4 expression of WAT was strongly enhanced by CDCA, whereas for female mice no significant difference was observed between CDCA and vehicle treated groups (Figs. 6A and B) . In conclusion, these results thereby indicated that CDCA induces GLUT4 expression in a sex-dependent manner. Male mice might be more sensitive than female ones to CDCA stimulation.
FXR does not interfere with the insulin-stimulated GLUT4 translocation to the cytomembrane
It has been well known that insulin can stimulate GLUT4 translocation from intracellular compartments to plasma membrane by activation of IRS-PI3K-Akt/PKB cascade [34] . While recent studies have even indicated that FXR may interfere with this pathway through its downstream genes, e.g. TRB3 and peroxisome proliferator-activated receptor α [35, 36] . With these facts in mind, we therefore investigated whether FXR could affect insulin's action on GLUT4 traffic by using a stable CHO (GLUT4) cell line. As indicated, in cells over-expressing FXR (Figs. 7A and B ) the GLUT4 proteins responded to insulin stimulation to the same extent as in cells transfected with a control vector (Figs. 7C and D), thereby implying that FXR might not impair insulinstimulated GLUT4's translocation to the cytomembrane. We next performed 2-Deoxyglucose uptake assay and observed that CDCA incubation had no influence on insulin-stimulated glucose uptake in 3T3-L1 adipocytes, consistent with the results in CHO (GLUT4) cell line (Fig. 7F) .
Discussion
As has been investigated, a variety of transcription factors and metabolic stimuli have been identified to exert positive or negative effects on GLUT4 expression, including several nuclear receptors such as LXR, NF-1, PPARγ and KLF-15 [11, 12, 31, 37] . Among these receptors, LXR has ever been confirmed as a positive regulator of GLUT4 gene [11, 38] , and LXR/FXR share some target genes like PLTP, apoE, and apoC-II [39] . Recently, some studies have also suggested the association between FXR and systemic glucose homeostasis [16, 26, 27] . All these facts thus have prompted us to perform the studies of FXR regulation in GLUT4 expression.
According to our investigations against 3T3-L1 and HepG2 cells, both FXR and its agonist CDCA could induce GLUT4 at the transcriptional and translational levels ( Figs. 1 and 2) . It was also observed that CDCA could increase the transcriptional level of PPAR-γ2 in 3T3-L1 adipose cells. Since PPAR-γ2 was indicated to repress GLUT4 promoter activity in primary adipocytes [37] , it does not seem that CDCA affected GLUT4 transcription through PPAR-γ2. Apart from the cellular level based assay, we also performed animal experiments, which indicated that the FXR endogenous agonist CDCA could obviously up-regulate WAT GLUT4 expression in male mice but not in female ones (Fig. 6 ). This sexdifference might be due to the following facts related to the sex hormones such as testosterone and 17β-estradiol. Firstly, sex-linked differences in the composition of liver/ gallbladder bile acids and the activity of 12β-hydroxylase have long been noted. Compared with male rats, female ones have higher proportions of CDCA [40, 41] . Secondly, sex hormones such as 17β-estradiol might have a remarkable influence on bile salt transport [42] . Finally, the fluctuant level of sex hormones might themselves affect GLUT4 expression [43] . As has been investigated, FXR induce GLUT4 expression through a PPARγ-and PI3K-independent manner (Figs. 2C, D and E), we thereby focused on the promoter of the GLUT4 gene. The mapping analysis, sitemutation and EMSA assays suggested a 40bp region responding to FXR, which was identified to contain a potential FXRE (Figs. 3 and 4) . According to the previous transgenic-mice based studies, the region (-412bp + 163bp) of human GLUT4 promoter is basal for transcription activity and tissue unrestricted [44] . While the investigations on the mouse GLUT4 promoter demonstrated that WAT enhancers are located between -1000bp and -442bp [45] . However, this identified FXRE does not lie in the tissue-specific and insulin-responsive promoter region, suggesting that FXR may contribute to the fundamental GLUT4 transcription. As shown in Figs. 3D and E, FXR deficiency not only antagonized the effect of CDCA, but also impaired the basal transcription of GLUT4, while the studies on GLUT4 mRNA level in embryonic fibroblasts derived from FXR-/-mice showed the similar results [16] . Besides, some transcription factors have also been reported to bind to the basal GLUT4 promoter [33, 46] .
We next investigated the potential binding model of FXR to the GLUT4-FXRE. It has been demonstrated that FXR, together with its heterodimeric partner RXR, displays a diversity of DNA binding models. To date, at least four models have been discovered: (I) FXR heterodimerizes with RXR and binds to FXREs, leading to up-regulation [47] or (II) down-regulation [48] of its target genes; FXR serves as a monomer by binding to (III) positive (RXR is indicated to inhibit FXR's binding to FXREs) [18] or [49] negative [21] FXREs. Moreover, in the conditon of model I RXR's agonist has been reported to augment the FXRE's response to FXR agonist [22, 50] On the contrary, other studies have indicated that RXR's agonist antagonizes FXR activity through not recruiting coactivators to FXR/RXR heterodimers and decreasing DNA binding [51, 52] . However, in our work, siRNA-mediated knock-down demonstrated that CDCAinduction of the GLUT4-FXRE is RXR-independent. Luciferase assay and EMSA based investigation also indicated that RXR does not interfere with FXR's binding to the FXRE in the GLUT4 promoter (Fig. 5) , which might be due to the GLUT4-FXRE containing only nuclear receptor half-site.
In addition, we also explored the potential effect of FXR on insulin-stimulated GLUT4 translocation, another important factor associated with glucose uptake. During the process of GLUT4-vesicle exocytosis, the phosphorylation of (Ser473) Akt plays a crucial role [53, 54] . Recent studies reported that FXR enhances TRB3 expression that in turn inhibits Akt phosphorylation and its activation [35, 36] . However, as for the insulininduced GLUT4 translocation efficiency, according to our study, obvious difference could be observed neither after FXR-over-expressing nor CDCA-stimulating (Fig. 7) . It is temporally suggested that such noninvolvement of FXR in GLUT4 translocation might be due to the possibility that FXR itself or its downstream genes may activate some signaling pathways, which further counterbalance the potential over-activation of FXR and the following negative effects on GLUT4 translocation.
Glucose uptake depends not only on insulinstimulated GLUT4 translocation, but also on the amount of the GLUT4 proteins stored in the cells [55] . Although there are contradictory opinions on whether decreased production of GLUT4 might cause insulin resistance, overexpression of GLUT4 in insulin target tissues has been regarded as one of the efficient therapeutic strategies for diabetic subjects [8, 9, 55] . Our present investigation hopefully might provide a new knowledge against GLUT4 transcription that FXR possibly functions as a molecular linker of BA-induced lipid absorption and GLUT4-mediated glucose utilization to keep energy balance. According to the previous studies, regulation of FXR by its ligand has already been considered as a promising therapy for dyslipidaemia and cholestasis [56] , our current findings are expected to supply new ideas for utilizing FXR in diabetes treatment, confirming that FXR may become a potential target for developing anti-diabetic agent. 
